Alzinova AB is Swedish biotechnology enterprise engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The company was founded in 2011 by the inventors of the AβCC peptide™ technology (patent pending) and MIVAC Development AB in close collaboration with the holding company at the University of Gothenburg in Sweden, GU Ventures AB.
The proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities towards several ends, including the discovery and development of novel therapeutics, research tools and services that enhance productivity within Alzheimer’s disease research. Alzinova is exploiting the unique properties of this non-fibrillogenic technology to develop therapeutics and diagnostics otherwise unavailable when using fibrillogenic peptides. The company focuses on development of a unique highly specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.